Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Anna Ludig, Francis Guillemin, Isabelle Chary-Valckenaere, Theo P. B. M. Suurmeijer, Torbjørn Moum, Wim J. A. van den Heuvel. (2000) Drug consumption in the first years of rheumatoid arthritis in France, the Netherlands, and Norway: A longitudinal study in the early nineties. Scandinavian Journal of Rheumatology 29:6, pages 352-357.
Read now
Read now
M. H. W. de Bois, J. W. Arndt, I. Speyer, E. K. J. Pauwels & F. C. Breedveld. (1996) Technetium-99m Labelled Human Immunoglobulin Scintigraphy Predicts Rheumatoid Arthritis in Patients with Arthralgia. Scandinavian Journal of Rheumatology 25:3, pages 155-158.
Read now
Read now
Articles from other publishers (28)
Joanna Kedra, Alexandre Lafourcade, Bernard Combe, Maxime Dougados, David Hajage & Bruno Fautrel. (2022) Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort. RMD Open 8:1, pages e002040.
Crossref
Crossref
Alan Tyndall. (2018) Hematopoietic stem cell transplantation for autoimmune diseases. Current Opinion in Hematology 25:6, pages 433-440.
Crossref
Crossref
Minyoung Her & Arthur Kavanaugh. (2015) Advances in use of immunomodulatory agents—a rheumatology perspective. Nature Reviews Gastroenterology & Hepatology 12:6, pages 363-368.
Crossref
Crossref
Izabela KorczowskaJan Krzysztof LackiPawel Hrycaj. (2013) Influence of Infliximab on Cytokines Network and Markers of Bone Remodeling in Rheumatoid Arthritis Patients. Yonsei Medical Journal 54:1, pages 183.
Crossref
Crossref
B. Fautrel. (2012) Economic benefits of optimizing anchor therapy for rheumatoid arthritis. Rheumatology 51:suppl 4, pages iv21-iv26.
Crossref
Crossref
Tuulikki Sokka, Pekka Hannonen & Heidi Mäkinen. (2011) Remission: a realistic goal in rheumatoid arthritis?. International Journal of Clinical Rheumatology 6:6, pages 643-647.
Crossref
Crossref
Bruno Fautrel, Suzanne M.M. Verstappen & Annelies Boonen. (2011) Economic consequences and potential benefits. Best Practice & Research Clinical Rheumatology 25:4, pages 607-624.
Crossref
Crossref
B. Fautrel, M. Benhamou, V. Foltz, N. Rincheval, A.-C. Rat, B. Combe, F. Berenbaum, P. Bourgeois & F. Guillemin. (2009) Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. Rheumatology 49:1, pages 147-155.
Crossref
Crossref
Loreto Massardo, María E. Suárez-Almazor, Mario H. Cardiel, Arnulfo Nava, Roger A. Levy, Ieda Laurindo, Enrique R. Soriano, Eduardo Acevedo-Vázquez, Alberto Millán, Carlos Pineda-Villaseñor, Claudio Galarza-Maldonado, Carlo V. Caballero-Uribe, Rolando Espinosa-Morales & Bernardo A. Pons-Estel. (2009) Management of Patients With Rheumatoid Arthritis in Latin America. JCR: Journal of Clinical Rheumatology 15:4, pages 203-210.
Crossref
Crossref
Izabela Korczowska, Anna Olewicz-Gawlik, Jakub Trefler, Paweł Hrycaj & Jan Krzysztof Łącki. (2007) Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients?. Clinical Rheumatology 27:5, pages 565-572.
Crossref
Crossref
Tuulikki Sokka. (2007) Quantitative assessment of rheumatoid arthritis in standard clinical care: turning clinical care into clinical science. Best Practice & Research Clinical Rheumatology 21:4, pages 653-661.
Crossref
Crossref
Kathryn Dao & John J. Cush. (2006) Acute polyarthritis. Best Practice & Research Clinical Rheumatology 20:4, pages 653-672.
Crossref
Crossref
T. Pincus & T. Sokka. (2006) Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients?. Rheumatology 45:5, pages 497-499.
Crossref
Crossref
Anand N. MALAVIYA. (2006) Clinical approach to patients with joint disease: importance of distinguishing inflammatory from non-inflammatory conditions. APLAR Journal of Rheumatology 9:1, pages 11-17.
Crossref
Crossref
Theodore Pincus, Tuulikki Sokka & Hannu Kautiainen. (2005) Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis & Rheumatism 52:4, pages 1009-1019.
Crossref
Crossref
Theodore Pincus & Tuulikki Sokka. (2004) Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care. Rheumatic Disease Clinics of North America 30:4, pages 725-751.
Crossref
Crossref
Izabela Korczowska, Pawel Hrycaj & Jan K Lacki. (2003) L’infliximab décroît-il le remodelage osseux chez les patients atteints de polyarthrite rhumatoïde ?. Revue du Rhumatisme 70:9, pages 783-784.
Crossref
Crossref
Izabela Korczowska, Pawel Hrycaj & Jan K. Lacki. (2003) Does infliximab decrease bone turnover in rheumatoid arthritis patients. Joint Bone Spine 70:5, pages 398-400.
Crossref
Crossref
Theodore Pincus, Allan Gibofsky & Michael E. Weinblatt. (2002) Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: Better treatments but a shortage of rheumatologists. Arthritis & Rheumatism 46:4, pages 851-854.
Crossref
Crossref
Theodore Pincus & Tuulikki Sokka. (2001) How can the risk of long-term consequences of rheumatoid arthritis be reduced?. Best Practice & Research Clinical Rheumatology 15:1, pages 139-170.
Crossref
Crossref
Jan K. Lacki. (2000) Management of the Patient with Severe Refractory Rheumatoid Arthritis. BioDrugs 13:6, pages 425-435.
Crossref
Crossref
Richard K. Burt & Ann E. Traynor. (2009) Hematopoietic Stem Cell Transplantation: A New Therapy for Autoimmune Disease. STEM CELLS 17:6, pages 366-372.
Crossref
Crossref
Richard K. Burt & Ann E. Traynor. (1999) Hematopoietic Stem Cell Transplantation: A New Therapy for Autoimmune Disease. The Oncologist 4:1, pages 77-83.
Crossref
Crossref
M Popovic, D Stefanovic, N Pejnovic, R Popovic, B Glisic, S Obradovic & M Dimitrijevic. (1998) Comparative study of the clinical efficacy of four dmards (leflunomide, methotrexate, cyclosporine, and levamisole) in patients with rheumatoid arthritis. Transplantation Proceedings 30:8, pages 4135-4136.
Crossref
Crossref
Waltraud Binder & Judith S Walker. (1998) Effect of the peripherally selective κ-opioid agonist, asimadoline, on adjuvant arthritis. British Journal of Pharmacology 124:4, pages 647-654.
Crossref
Crossref
Jodie L. Wilson, Vim Nayanar & Judith S. Walker. (2012)
The site of anti‐arthritic action of the
K
‐opioid, U‐50,488H, in adjuvant arthritis: importance of local administration
. British Journal of Pharmacology 118:7, pages 1754-1760.
Crossref
Crossref
Leigh F. Callahan & Theodore Pincus. (2005) Mortality in the rheumatic diseases. Arthritis & Rheumatism 8:4, pages 229-241.
Crossref
Crossref
M. H. W. de Bois, M. -L. Westedt, J. W. Arndt, K. S. Wiarda, E. A. van der Velde, E. K. J. Pauwels & F. C. Breedveld. (1995) Value of 99mTc-IgG scintigraphy in the prediction of joint destruction in patients with rheumatoid arthritis of recent onset. Rheumatology International 15:4, pages 155-158.
Crossref
Crossref